Brought to you by 
Shire acquires Noven's MethyPatch; Noven reacquires rights
04 Jan 2022
Executive Summary
Shire Pharmaceuticals (central nervous system, cancer, and anti-infective drugs) has acquired Noven Pharmaceuticals' (transdermal drug delivery) MethyPatch (methylphenidate), a once-daily patch to treat attention deficit hyperactivity disorder (ADHD), which has been awaiting FDA approval since June 2002.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire acquires Noven's MethyPatch; Noven reacquires rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice